CN101631552A - 双糖链蛋白聚糖或双糖链蛋白聚糖活性增强剂在制备药物组合物中的用途 - Google Patents
双糖链蛋白聚糖或双糖链蛋白聚糖活性增强剂在制备药物组合物中的用途 Download PDFInfo
- Publication number
- CN101631552A CN101631552A CN200880007865A CN200880007865A CN101631552A CN 101631552 A CN101631552 A CN 101631552A CN 200880007865 A CN200880007865 A CN 200880007865A CN 200880007865 A CN200880007865 A CN 200880007865A CN 101631552 A CN101631552 A CN 101631552A
- Authority
- CN
- China
- Prior art keywords
- disaccharidase catenin
- catenin polysaccharide
- disaccharidase
- polysaccharide
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 280
- 102000016362 Catenins Human genes 0.000 title claims abstract description 277
- 108010067316 Catenins Proteins 0.000 title claims abstract description 277
- 108010001394 Disaccharidases Proteins 0.000 title claims abstract description 275
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 274
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 274
- 239000012744 reinforcing agent Substances 0.000 title claims abstract description 37
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 81
- 210000002216 heart Anatomy 0.000 claims abstract description 60
- 230000000694 effects Effects 0.000 claims abstract description 50
- 208000028867 ischemia Diseases 0.000 claims abstract description 48
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 29
- 201000010099 disease Diseases 0.000 claims abstract description 27
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 26
- 230000000302 ischemic effect Effects 0.000 claims abstract description 15
- 230000002265 prevention Effects 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 97
- 210000004027 cell Anatomy 0.000 claims description 78
- 102000004169 proteins and genes Human genes 0.000 claims description 57
- 230000014509 gene expression Effects 0.000 claims description 52
- 102000039446 nucleic acids Human genes 0.000 claims description 29
- 108020004707 nucleic acids Proteins 0.000 claims description 29
- 150000007523 nucleic acids Chemical class 0.000 claims description 28
- 208000031225 myocardial ischemia Diseases 0.000 claims description 22
- 210000000056 organ Anatomy 0.000 claims description 22
- 241001597008 Nomeidae Species 0.000 claims description 18
- 230000001256 tonic effect Effects 0.000 claims description 18
- 102000004237 Decorin Human genes 0.000 claims description 17
- 108090000738 Decorin Proteins 0.000 claims description 17
- 201000005577 familial hyperlipidemia Diseases 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 239000012190 activator Substances 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 10
- 230000004913 activation Effects 0.000 claims description 10
- 238000001476 gene delivery Methods 0.000 claims description 10
- 102000003137 synaptotagmin Human genes 0.000 claims description 10
- 108060008004 synaptotagmin Proteins 0.000 claims description 10
- 230000005961 cardioprotection Effects 0.000 claims description 9
- 230000008521 reorganization Effects 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 206010019280 Heart failures Diseases 0.000 claims description 7
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims description 7
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims description 7
- 102000015636 Oligopeptides Human genes 0.000 claims description 6
- 108010038807 Oligopeptides Proteins 0.000 claims description 6
- 101150094745 Ptk2b gene Proteins 0.000 claims description 6
- 238000002493 microarray Methods 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 5
- 230000000489 anti-atherogenic effect Effects 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 230000005754 cellular signaling Effects 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 229960004025 sodium salicylate Drugs 0.000 claims description 4
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 claims description 3
- 229930188226 Lysolipin Natural products 0.000 claims description 3
- 208000034189 Sclerosis Diseases 0.000 claims description 3
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 210000001715 carotid artery Anatomy 0.000 claims description 3
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 208000026758 coronary atherosclerosis Diseases 0.000 claims description 3
- NEOMIZJYHXSRLV-UHFFFAOYSA-N lysolipin Chemical compound O1C2=C(OC)C(Cl)=CC=C2C(=O)C2=C1C(OCO1)=C3C1C(OC)C(C=C1C(O)C(N(C(=O)C1=C1O)C)OC)=C1C3=C2O NEOMIZJYHXSRLV-UHFFFAOYSA-N 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229930193551 sterin Natural products 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000012216 screening Methods 0.000 abstract description 13
- 238000002360 preparation method Methods 0.000 abstract description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 38
- 210000001519 tissue Anatomy 0.000 description 35
- 230000009261 transgenic effect Effects 0.000 description 35
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 30
- 241001465754 Metazoa Species 0.000 description 29
- 230000003293 cardioprotective effect Effects 0.000 description 21
- 108090001138 Biglycan Proteins 0.000 description 20
- 102000004954 Biglycan Human genes 0.000 description 19
- 241000699660 Mus musculus Species 0.000 description 18
- 238000011830 transgenic mouse model Methods 0.000 description 18
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 16
- 210000001671 embryonic stem cell Anatomy 0.000 description 15
- 101150102415 Apob gene Proteins 0.000 description 14
- 210000004165 myocardium Anatomy 0.000 description 14
- 235000015961 tonic Nutrition 0.000 description 14
- 206010002660 Anoxia Diseases 0.000 description 13
- 241000976983 Anoxia Species 0.000 description 13
- 206010021143 Hypoxia Diseases 0.000 description 13
- 230000007953 anoxia Effects 0.000 description 13
- 235000012000 cholesterol Nutrition 0.000 description 13
- 230000001939 inductive effect Effects 0.000 description 12
- 235000012054 meals Nutrition 0.000 description 12
- 238000011160 research Methods 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 11
- 206010061216 Infarction Diseases 0.000 description 10
- 108020004511 Recombinant DNA Proteins 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 101710132601 Capsid protein Proteins 0.000 description 9
- 102000016611 Proteoglycans Human genes 0.000 description 9
- 108010067787 Proteoglycans Proteins 0.000 description 9
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 9
- 230000000747 cardiac effect Effects 0.000 description 9
- 210000002064 heart cell Anatomy 0.000 description 9
- 230000007574 infarction Effects 0.000 description 9
- 238000006213 oxygenation reaction Methods 0.000 description 9
- 102100030401 Biglycan Human genes 0.000 description 8
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 8
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 8
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 8
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 8
- 210000000709 aorta Anatomy 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000002107 myocardial effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 206010063837 Reperfusion injury Diseases 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 230000005986 heart dysfunction Effects 0.000 description 7
- 210000005003 heart tissue Anatomy 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 230000010412 perfusion Effects 0.000 description 7
- 150000004804 polysaccharides Polymers 0.000 description 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- 229920002683 Glycosaminoglycan Polymers 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- 108010029485 Protein Isoforms Proteins 0.000 description 6
- 102000001708 Protein Isoforms Human genes 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 210000004351 coronary vessel Anatomy 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 230000006978 adaptation Effects 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000018616 Apolipoproteins B Human genes 0.000 description 4
- 108010027006 Apolipoproteins B Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- 102000013275 Somatomedins Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000002459 blastocyst Anatomy 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000039 congener Substances 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000010016 myocardial function Effects 0.000 description 4
- 210000000107 myocyte Anatomy 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000010188 recombinant method Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 3
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 3
- 229920001287 Chondroitin sulfate Polymers 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 3
- 229920000045 Dermatan sulfate Polymers 0.000 description 3
- 101100310816 Dictyostelium discoideum splB gene Proteins 0.000 description 3
- 102000018693 Focal Adhesion Kinase 2 Human genes 0.000 description 3
- 108010091820 Focal Adhesion Kinase 2 Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 3
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 description 3
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
- 108010021843 fluorescent protein 583 Proteins 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229910010272 inorganic material Inorganic materials 0.000 description 3
- 230000002530 ischemic preconditioning effect Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 102000016951 Chemokine CXCL2 Human genes 0.000 description 2
- 108010014414 Chemokine CXCL2 Proteins 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 2
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000009787 cardiac fibrosis Effects 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 2
- 229940051593 dermatan sulfate Drugs 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 210000003725 endotheliocyte Anatomy 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000006345 epimerization reaction Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- MURGITYSBWUQTI-UHFFFAOYSA-N fluorescin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 210000003709 heart valve Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 208000037906 ischaemic injury Diseases 0.000 description 2
- 208000023589 ischemic disease Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000002969 morbid Effects 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- -1 polysaccharide nucleic acid Chemical class 0.000 description 2
- 230000010411 postconditioning Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000009168 stem cell therapy Methods 0.000 description 2
- 238000009580 stem-cell therapy Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 description 1
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- LZLVZIFMYXDKCN-QJWFYWCHSA-N 1,2-di-O-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC LZLVZIFMYXDKCN-QJWFYWCHSA-N 0.000 description 1
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
- OYXZMSRRJOYLLO-UHFFFAOYSA-N 7alpha-Hydroxycholesterol Natural products OC1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 OYXZMSRRJOYLLO-UHFFFAOYSA-N 0.000 description 1
- OYXZMSRRJOYLLO-KGZHIOMZSA-N 7beta-hydroxycholesterol Chemical compound C([C@@H]1O)=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 OYXZMSRRJOYLLO-KGZHIOMZSA-N 0.000 description 1
- 101150059573 AGTR1 gene Proteins 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000002110 C2 domains Human genes 0.000 description 1
- 108050009459 C2 domains Proteins 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000001045 Connexin 43 Human genes 0.000 description 1
- 108010069241 Connexin 43 Proteins 0.000 description 1
- 241000766026 Coregonus nasus Species 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010044495 Fetal Hemoglobin Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000006334 Gingival Fibromatosis Diseases 0.000 description 1
- 101150039660 HA gene Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000998969 Homo sapiens Inositol-3-phosphate synthase 1 Proteins 0.000 description 1
- 101000932178 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP4 Proteins 0.000 description 1
- 101000878253 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP5 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000000521 Immunophilins Human genes 0.000 description 1
- 108010016648 Immunophilins Proteins 0.000 description 1
- 102100036881 Inositol-3-phosphate synthase 1 Human genes 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000004289 Interferon regulatory factor 1 Human genes 0.000 description 1
- 108090000890 Interferon regulatory factor 1 Proteins 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical compound OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
- 101000756628 Mus musculus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 102000018546 Paxillin Human genes 0.000 description 1
- ACNHBCIZLNNLRS-UHFFFAOYSA-N Paxilline 1 Natural products N1C2=CC=CC=C2C2=C1C1(C)C3(C)CCC4OC(C(C)(O)C)C(=O)C=C4C3(O)CCC1C2 ACNHBCIZLNNLRS-UHFFFAOYSA-N 0.000 description 1
- 102100020739 Peptidyl-prolyl cis-trans isomerase FKBP4 Human genes 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- WOUIMBGNEUWXQG-VKHMYHEASA-N Ser-Gly Chemical compound OC[C@H](N)C(=O)NCC(O)=O WOUIMBGNEUWXQG-VKHMYHEASA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 102000001732 Small Leucine-Rich Proteoglycans Human genes 0.000 description 1
- 108010040068 Small Leucine-Rich Proteoglycans Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108010055170 Synaptotagmin I Proteins 0.000 description 1
- 102100036417 Synaptotagmin-1 Human genes 0.000 description 1
- 108700031954 Tgfb1i1/Leupaxin/TGFB1I1 Proteins 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 230000000931 anti-neutrophil effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000006502 antiplatelets effects Effects 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000009091 contractile dysfunction Effects 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- 238000004044 disperse dyeing Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000020 effect on hyperlipemia Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 210000003976 gap junction Anatomy 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- ACNHBCIZLNNLRS-UBGQALKQSA-N paxilline Chemical compound N1C2=CC=CC=C2C2=C1[C@]1(C)[C@@]3(C)CC[C@@H]4O[C@H](C(C)(O)C)C(=O)C=C4[C@]3(O)CC[C@H]1C2 ACNHBCIZLNNLRS-UBGQALKQSA-N 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000011172 small scale experimental method Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000037905 systemic hypertension Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4722—Proteoglycans, e.g. aggreccan
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7019—Ischaemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
点 | 抗体名称 | Sigma登录号 | 过表达倍数 |
5.1Dab | i-NOS | N7782 | 1.67 |
5.2Dab | n-NOS | N7155 | 2.20 |
5.3Dab | e-NOS | N2643 | 2.14 |
6.3Cab | 突触结合蛋白 | S2177 | 1.83 |
7.4Cab | Mcl-1 | M8434 | 1.83 |
8.1Dab | Pyk2 | P3902 | 1.99 |
Claims (19)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUP0700024 | 2007-01-11 | ||
HU0700024A HU0700024D0 (en) | 2007-01-11 | 2007-01-11 | Use of enhancers in biglycan activuty in the preparation of pharmaceutical compositions having utility in cardiac diseases |
PCT/HU2008/000003 WO2008084268A1 (en) | 2007-01-11 | 2008-01-10 | Use of biglycan or enhancers of biglycan activity in the preparation of pharmaceutical compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101631552A true CN101631552A (zh) | 2010-01-20 |
CN101631552B CN101631552B (zh) | 2013-08-07 |
Family
ID=89987257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008800078653A Expired - Fee Related CN101631552B (zh) | 2007-01-11 | 2008-01-10 | 双糖链蛋白聚糖或双糖链蛋白聚糖活性增强剂在制备药物组合物中的用途 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20100087362A1 (zh) |
EP (1) | EP2124962B1 (zh) |
JP (1) | JP2010517940A (zh) |
CN (1) | CN101631552B (zh) |
HU (1) | HU0700024D0 (zh) |
WO (1) | WO2008084268A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112022870A (zh) * | 2011-10-17 | 2020-12-04 | 医药匈牙利2000有限公司 | 用于治疗缺血性损伤的化合物 |
CN115697352A (zh) * | 2020-03-19 | 2023-02-03 | 格莱克罗吉克斯公司 | 作为蛋白聚糖模拟物的硫酸化糖胺聚糖生物材料 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102187228A (zh) * | 2008-10-17 | 2011-09-14 | 霍夫曼-拉罗奇有限公司 | 双糖链蛋白聚糖在心力衰竭评估中的用途 |
AU2013329296B2 (en) * | 2012-10-10 | 2017-11-09 | Brown University | Biglycan variant polypeptides and methods of use |
EP2832362A1 (en) * | 2013-08-01 | 2015-02-04 | Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. | glycosylated protein of an extra-cellular matrix for use in a method of treating an ischemic heart of a human or animal subject in need thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE349046B (zh) | 1966-12-23 | 1972-09-18 | C Guevne | |
JPH07508403A (ja) * | 1992-04-03 | 1995-09-21 | ラ ホヤ キャンサー リサーチ ファウンデーション | デコリンフラグメントおよび細胞調節因子を阻害する方法 |
US5650389A (en) * | 1993-03-01 | 1997-07-22 | University Of Alabama At Birmingham Research Foundation | Methods for the inhibition of complement activation |
AU6926194A (en) * | 1994-05-09 | 1995-11-29 | Boehringer Mannheim Gmbh | Use of chondroitin sulphate proteoglycans for protection of neurons |
EP1478758A4 (en) * | 2002-02-01 | 2006-08-30 | Medstar Res Inst | POLYMORPHISMS IN ELASTIN, FIBRILLIN AND RELATED GENES THAT AROSE RESTENOSIS AND ATHEROSCLEROSIS |
WO2008070117A1 (en) * | 2006-12-04 | 2008-06-12 | Promedior, Inc. | Conjoint therapy for treating fibrotic diseases |
-
2007
- 2007-01-11 HU HU0700024A patent/HU0700024D0/hu unknown
-
2008
- 2008-01-10 EP EP08702170.5A patent/EP2124962B1/en active Active
- 2008-01-10 CN CN2008800078653A patent/CN101631552B/zh not_active Expired - Fee Related
- 2008-01-10 JP JP2009545242A patent/JP2010517940A/ja active Pending
- 2008-01-10 WO PCT/HU2008/000003 patent/WO2008084268A1/en active Application Filing
- 2008-01-10 US US12/448,862 patent/US20100087362A1/en not_active Abandoned
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112022870A (zh) * | 2011-10-17 | 2020-12-04 | 医药匈牙利2000有限公司 | 用于治疗缺血性损伤的化合物 |
CN112022870B (zh) * | 2011-10-17 | 2024-05-10 | 医药匈牙利2000有限公司 | 用于治疗缺血性损伤的化合物 |
CN115697352A (zh) * | 2020-03-19 | 2023-02-03 | 格莱克罗吉克斯公司 | 作为蛋白聚糖模拟物的硫酸化糖胺聚糖生物材料 |
Also Published As
Publication number | Publication date |
---|---|
HU0700024D0 (en) | 2007-03-28 |
EP2124962A1 (en) | 2009-12-02 |
WO2008084268A1 (en) | 2008-07-17 |
US20100087362A1 (en) | 2010-04-08 |
CN101631552B (zh) | 2013-08-07 |
JP2010517940A (ja) | 2010-05-27 |
EP2124962B1 (en) | 2014-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Goncharov et al. | Markers and biomarkers of endothelium: when something is rotten in the state | |
Force et al. | Growth factors and mitogen-activated protein kinases | |
Sussman et al. | Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1 | |
Isenberg et al. | CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1 | |
Iismaa et al. | Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders | |
CN101631552B (zh) | 双糖链蛋白聚糖或双糖链蛋白聚糖活性增强剂在制备药物组合物中的用途 | |
US20060035851A1 (en) | Use of hmgb1 in the treatment of tissue damage and or to promote tissue repair | |
Rana et al. | Nanotized PPARα overexpression targeted to hypertrophied myocardium improves cardiac function by attenuating the p53-GSK3β-mediated mitochondrial death pathway | |
Baxter | Signaling pathways of the insulin-like growth factor binding proteins | |
Biyashev et al. | Natural angiogenesis inhibitor signals through Erk5 activation of peroxisome proliferator-activated receptor γ (PPARγ) | |
JP2008501725A (ja) | グリカンに特異的な受容体として機能するインテグリンを介したグリコシルホスファチジルイノシトールグリカンシグナル伝達 | |
US20070238663A1 (en) | Use of HMGB1 to promote stem cell migration and/or proliferation | |
Meyer et al. | A recombinant antibody increases cardiac contractility by mimicking phospholamban phosphorylation | |
Schevzov et al. | Divergent regulation of the sarcomere and the cytoskeleton | |
US20070135365A1 (en) | Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiovascular disease caused thereby | |
CN101610780A (zh) | 羧化不足/未羧化的骨钙蛋白提高β-细胞增殖、胰岛素分泌、胰岛素敏感性、葡萄糖耐量并降低脂肪量 | |
Niizeki et al. | Cardiac-specific overexpression of diacylglycerol kinase ζ attenuates left ventricular remodeling and improves survival after myocardial infarction | |
US8193150B2 (en) | Improving vascular function with an inactivating mutant of a TRPC channel protein | |
KR20190137786A (ko) | 뇌 오스테오칼신 수용체 및 인지 장애 | |
Naito-Matsui | Physiological Significance of Animal-and Tissue-specific Sialic Acid Composition | |
WO2007050648A9 (en) | Use of tumor necrosis factor- receptor p75 for treatment of ischemia-induced neovascularization | |
Wills | SUMOylation of the B2AR influences receptor internalisation, desensitisation and downstream signalling | |
Abdelaziz | The Protective Effects of Remote Ischaemic Preconditioning on Pressure Overload-Induced Myocardial Remodelling | |
AU2004287376A1 (en) | Methods and compositions using adiponectin for treatment of cardiac disorders and for stimulation of angiogenesis | |
Liu | Role Of Nitric Oxide In Embryonic Heart Development And Adult Aortic Valve Disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: PHARMACEUTICAL HUNGARY 2000 KFT. Free format text: FORMER OWNER: MTA SZEGEDI BIOLOGIAI KOEZPONT Effective date: 20130424 Free format text: FORMER OWNER: PHARMACEUTICAL HUNGARY 2000 KFT. Effective date: 20130424 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: Szeged Applicant after: Szeged biological research center MTA point Applicant after: Hungary Pharmaceutical 2000 Ltd. Address before: Szeged Applicant before: MTA SZEGEDI BIOLOG KOEZPONT Applicant before: Hungary Pharmaceutical 2000 Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: MTA SZEGEDI BIOLOG KOEZPONT TO: MTA SZEGEDI BIOLOGIAI KOEZPONT |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20130424 Address after: Szeged Applicant after: Hungary Pharmaceutical 2000 Ltd. Address before: Szeged Applicant before: Szeged biological research center MTA point Applicant before: Hungary Pharmaceutical 2000 Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130807 Termination date: 20200110 |